Browse > Article
http://dx.doi.org/10.3904/kjim.2010.25.4.345

The Role of Photodynamic Therapy for Hilar Cholangiocarcinoma  

Cheon, Young-Koog (Institute for Digestive Research and Digestive Disease Center, Soonchunhyang University College of Medicine)
Publication Information
The Korean journal of internal medicine / v.25, no.4, 2010 , pp. 345-352 More about this Journal
Abstract
The prognosis for hilar cholangiocarcinoma is limited by tumor spread along the biliary tree leading to refractory obstructive cholestasis, cholangitis, and liver failure. Palliation with biliary endoprostheses results in median survival times of 4-6 months for advanced bile duct cancer. Photodynamic therapy (PDT) is a local photochemical tumor treatment consisting of a photosensitizing agent combined with laser irradiation of a distinct wavelength. Tumor ablation with PDT combined with biliary stenting reduces cholestasis and significantly improves median survival time. However, the treatment is not widely available, and the photosensitizers used for PDT cause prolonged photosensitivity. Optimum control of tumor spread along the bile ducts and control of cholestasis and cholangitis will prolong survival in one to two thirds of patients, and renders them suitable for other antitumor therapies.
Keywords
Cholangiocarcinoma; Bile duct neoplasms; Photodynamic therapy; Photosensitizing agents;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 Kremer B, Henne-Bruns D, Vogel I, Grimm H, Soehendra N. Impact of staging on treatment of biliary carcinoma. Endoscopy 1993;25:92-99.   DOI   ScienceOn
2 Molt P, Hopfan S, Watson RC, Botet JF, Brennan MF. Intraluminal radiation therapy in the management of malignant biliary obstruction. Cancer 1986;57:536-544.   DOI   ScienceOn
3 Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004;60:68-75.   DOI   ScienceOn
4 Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 1998;150(5 Suppl):S146-S156.   DOI
5 Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999;49(3 Pt 2):S20-S23.   DOI   ScienceOn
6 Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002;20:3-7.   DOI   ScienceOn
7 Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 2003;97:2783-2790.   DOI   ScienceOn
8 Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000;31:291-298.   DOI   ScienceOn
9 Cheon YK, Cho YD, Baek SH, et al. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol 2004;44:280-287.
10 Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996;39:852-855.   DOI   ScienceOn
11 Pahernik SA, Dellian M, Berr F, Tannapfel A, Wittekind C, Goetz AE. Distribution and pharmacokinetics of Photofrin in human bile duct cancer. J Photochem Photobiol B 1998;47:58-62.   DOI   ScienceOn
12 Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res 1976;36(7 Pt 1):2326-2329.
13 Henderson BW, Donovan JM. Release of prostaglandin $E_2$ from cells by photodynamic treatment in vitro. Cancer Res 1989;49(24 Pt 1):6896-6900.
14 Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-542.   DOI   ScienceOn
15 Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001;53:500-504.   DOI   ScienceOn
16 Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998;228:385-394.   DOI   ScienceOn
17 Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol 1997;9:481-484.   DOI   ScienceOn
18 Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994;344:1655-1660.   DOI   ScienceOn
19 Polydorou AA, Cairns SR, Dowsett JF, et al. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 1991;32:685-689.   DOI   ScienceOn
20 Ducreux M, Liguory C, Lefebvre JF, et al. Management of malignant hilar biliary obstruction by endoscopy. Results and prognostic factors. Dig Dis Sci 1992;37:778-783.   DOI   ScienceOn
21 Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998;47:354-362.   DOI   ScienceOn
22 Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492.   DOI   ScienceOn
23 Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004;139:514-523.   DOI   ScienceOn
24 Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-517.   DOI   ScienceOn
25 Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005;100:2426-2430.   DOI   ScienceOn
26 Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355-1363.   DOI   ScienceOn
27 Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol 2004;39:1095-1101.   DOI   ScienceOn
28 Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamaoka T. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 1990;145:397-403.
29 Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998;227:398-404.   DOI   ScienceOn
30 Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007;102:2164-2170.   DOI   ScienceOn
31 Shim CS, Cheon YK, Cha SW, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005;37:425-433.   DOI   ScienceOn
32 Wong M, Wang KK, Alexander Gl, et al. Cholorin E6 and hematophorphyrin derivative (HPD) on photodynamic therapy of a human cholangiocarcinoma model [abstract]. Gastroenterology 1996;110:595.
33 McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg 1991;126:111-113.   DOI   ScienceOn
34 Wong Kee Song LM, Wang KK, Zinsmeister AR. Mono-Laspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 1998;82:421-427.   DOI   ScienceOn
35 Cheon YK, Kim YS, Cho YD, et al. Experimental interstitial photodynamic therapy of the Morris 7777 hepatoma in the rat. Korean J Med 2004;66:397-403.